Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + tislelizumab perioperative therapy in resectable hepatocellular carcinoma
ChiCTR2400084971Phase 2Not yet recruiting
- Sponsor
- Eighth Affiliated Hospital of Sun Yat-sen University
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by Eighth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Recurrence-free survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400084971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084971.